M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Phase 1

Active, not recruiting

Conditions: Recurrent Anaplastic Large Cell Lymphoma
Recurrent Mycosis Fungoides
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory Mycosis Fungoides
Refractory Anaplastic Large Cell Lymphoma
Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified
Recurrent Classic Hodgkin Lymphoma
Refractory Classic Hodgkin Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma

Interventions: Biological: Anti-CD30/CD16A Monoclonal Antibody AFM13
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Fludarabine Phosphate
Biological: Genetically Engineered Lymphocyte Therapy

First Posted Date: 2019-08-30

Last Posted Date: 2025-04-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT04074746

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study

Phase 2

Terminated

Conditions: Malignant Ovarian Neoplasm
Malignant Anal Neoplasm
Malignant Prostate Neoplasm
Low Anterior Resection Syndrome
Malignant Uterine Neoplasm
Malignant Vulvar Neoplasm
Malignant Bladder Neoplasm
Malignant Cervical Neoplasm
Malignant Pelvic Neoplasm
Rectal Carcinoma

Interventions: Procedure: Explantation
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Device: Sacral Nerve Stimulator
Device: Sacral Nerve Stimulator Battery
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2019-08-26

Last Posted Date: 2023-08-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT04066894

Locations: 🇺🇸
MD Anderson in Sugar Land, Sugar Land, Texas, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

nTMS in Planning Stereotactic Radiosurgery in Patients With Brain Metastases in the Motor Cortex

Not Applicable

Active, not recruiting

Conditions: Radiation Therapy Recipient
Metastatic Malignant Neoplasm in the Brain

Interventions: Behavioral: Hand Function Test
Procedure: Navigated Transcranial Magnetic Stimulation
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2019-08-20

Last Posted Date: 2025-01-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT04062305

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

Phase 2

Active, not recruiting

Conditions: Hematologic and Lymphocytic Disorder
Therapy-Related Acute Myeloid Leukemia
FLT3 Gene Mutation
Acute Myeloid Leukemia
Minimal Residual Disease Persistence
Acute Myeloid Leukemia in Remission

Interventions: Drug: Azacitidine
Drug: Venetoclax

First Posted Date: 2019-08-20

Last Posted Date: 2025-03-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT04062266

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer

Phase 2

Withdrawn

Conditions: Metastatic Pancreatic Adenocarcinoma
Stage IV Pancreatic Cancer AJCC v8

Interventions: Biological: Pegylated Recombinant Human Hyaluronidase PH20
Biological: Pembrolizumab

First Posted Date: 2019-08-16

Last Posted Date: 2020-03-13

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT04058964

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

An Investigational Device (Millar Mikro-Tip Catheter) and Imaging Scan (Shear Wave Elastography) in Measuring Tumor Pressure and Stiffness in Patients With Solid Tumors Undergoing Ultrasound-Guided Biopsy

Not Applicable

Active, not recruiting

Conditions: Solid Neoplasm

Interventions: Device: Shear Wave Elastography
Procedure: Tumor Interstitial Fluid Pressure Measurement

First Posted Date: 2019-08-13

Last Posted Date: 2025-05-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 27

Registration Number: NCT04054154

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Phase 2

Recruiting

Conditions: Recurrent Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma

Interventions: Drug: Low Dose Radiation Therapy

First Posted Date: 2019-08-13

Last Posted Date: 2025-02-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT04054167

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Phase 2

Withdrawn

Conditions: Myelofibrosis Transformation in Essential Thrombocythemia
Primary Myelofibrosis
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase

Interventions: Drug: LOXL2 Inhibitor PAT-1251
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2019-08-13

Last Posted Date: 2019-08-13

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT04054245

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Financial Distress in Advanced Cancer Patients

Active, not recruiting

Conditions: Advanced Malignant Neoplasm
Recurrent Malignant Neoplasm
Locally Advanced Malignant Neoplasm
Metastatic Malignant Neoplasm
Refractory Malignant Neoplasm

Interventions: Other: Medical Chart Review
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2019-08-12

Last Posted Date: 2024-10-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 141

Registration Number: NCT04053517

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Phase 2

Terminated

Conditions: Refractory Mantle Cell Lymphoma
Recurrent Mantle Cell Lymphoma

Interventions: Drug: Ixazomib
Drug: Ixazomib Citrate
Biological: Rituximab

First Posted Date: 2019-08-07

Last Posted Date: 2025-04-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT04047797

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy